

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE
in its capacity as elected Office

Date of mailing (day/month/year) 17 July 2001 (17.07.01)	
International application No. PCT/US00/27210	Applicant's or agent's file reference 2847-56232
International filing date (day/month/year) 02 October 2000 (02.10.00)	Priority date (day/month/year) 01 October 1999 (01.10.99)
Applicant HINTZ, William, E. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
27 April 2001 (27.04.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Odile ALIU
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

WRITTEN OPINION

(PCT Rule 66)

To: **PAULA A. DE GRANDIS**
KLARQUIST, SPARKMAN, CAMPBELL, LEIGH &
WHINSTON, LLP
ONE WORLD TRADE CENTER, SUITE 1600
121 SW SALMON STREET
PORTLAND, OR 97204

SLR

Date of Mailing
(day/month/year)

17 AUG 2001

Applicant's or agent's file reference
2847-56232

REPLY DUE within **TWO** months
from the above date of mailing

International application No.
PCT/US00/27210

International filing date (day/month/year)
02 OCTOBER 2000

Priority date (day/month/year)
01 OCTOBER 1999

International Patent Classification (IPC) or both national and
IPC(7): **C12N 9/00, 9/24, 15/09, 1/20; C07K, 16/00**

IPC
5/69.2, 183, 200; 530/389.1

Applicant
UNIVERSITY OF VICTORIA INNOVATION AND DEVELOPMENT CORPORATION

1. This written opinion is the first (first, etc.) drawn by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- | | | | |
|------|-------------------------------------|--|---|
| I | <input checked="" type="checkbox"/> | Basis of the opinion | <p>DOCKETED FOR: 10/17/01</p> <p>COMPUTER <input checked="" type="checkbox"/></p> <p>CARD <input checked="" type="checkbox"/></p> <p>BOOK <input checked="" type="checkbox"/></p> <p>DRAWER <input checked="" type="checkbox"/></p> <p>BKPR <input checked="" type="checkbox"/></p> <p>ANN SVF <input checked="" type="checkbox"/></p> |
| II | <input type="checkbox"/> | Priority | |
| III | <input type="checkbox"/> | Non-establishment of opinion with regard to novelty, inventive step or industrial applicability | |
| IV | <input type="checkbox"/> | Lack of unity of invention | |
| V | <input checked="" type="checkbox"/> | Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement | |
| VI | <input type="checkbox"/> | Certain documents cited | |
| VII | <input type="checkbox"/> | Certain defects in the international application | |
| VIII | <input type="checkbox"/> | Certain observations on the international application | |

3. The applicant is hereby invited to reply to this opinion.

When? See the time limit indicated above. ~~The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).~~

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 *bis*.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: **01 FEBRUARY 2002**

Name and mailing address of the IPEA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

TERRY J. DEY

MANJUNATH RAO

PARALEGAL SPECIALIST
TECHNOLOGY CENTER 1600

Telephone No. (703) 308-0196

WRITTEN OPINION

International application No.

PCT/US00/27210

I. Basis of the opinion

1. With regard to the elements of the international application:*

☒ the international application as originally filed

☒ the description:

pages 1-44 , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of

☒ the claims:

pages 45-47 , as originally filed
pages NONE , as amended (together with any statement) under Article 19
pages NONE , filed with the demand
pages NONE , filed with the letter of

☒ the drawings:

pages 1-22 , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of

☒ the sequence listing part of the description:

pages 1-13 , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the written opinion was drawn on the basis of the sequence listing:

- ☒ contained in the international application in printed form.
☒ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority in written form.
☐ furnished subsequently to this Authority in computer readable form.
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

- ☒ the description, pages NONE
☒ the claims, Nos. NONE
☒ the drawings, sheets/fig NONE

5. ☐ This opinion has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. statement**

Novelty (N)	Claims <u>2, 7</u>	YES
	Claims <u>1, 3-6, 8-14</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-14</u>	NO
Industrial Applicability (IA)	Claims <u>NONE</u>	YES
	Claims <u>NONE</u>	NO

2. citations and explanations

Claims 1, 3-6, 8-14 lack novelty under PCT Article 33(2) as being anticipated by Inoue et al.

Claims 1, 3-6, 8-14 are drawn to a purified protein having mannosidase activity comprising an amino acid sequence selected from the group consisting of a) SEQ ID NOs: 3, 6, and 18, b) a conservative variant, or c) amino acid sequences having at least 60% sequence identity to the sequences specified in a) (claim 1), an isolated nucleic acid encoding the same, vector, host cell, a method for altering glycosylation pattern of a macromolecule (claims 3-6, 8-10), an isolated nucleic acid comprising a sequence selected from the group consisting of at least 15 nucleotides of SEQ ID NO: 1 (claim 11(a)), a method for altering glycosylation pattern (claim 12), a method for isolating nucleic acid sequence encoding a mannosidase and a mannosidase identified by the above method (claims 13-14). Inoue et al. disclose a the isolation and identification of a mannosidase that is more than 60% identical to SEQ ID NO: 6 and also disclose a nucleic acid encoding a mannosidase which is at least 15 nucleotides identical to SEQ ID NO: 1, and the above described methods. Therefore Inoue et al. anticipate claims 1, 3-6, 8-14 of the instant application as written.

Claim 11 lacks novelty under PCT Article 33(2) as being anticipated by Kupfer et al.

Claim 11 is drawn to an isolated nucleic acid molecule comprising a sequence selected from a group consisting of at least 15, 20, 30 nucleotides of SEQ ID NO: 1, 4 or 17. Kupfer et al. disclose a nucleic acid molecule comprising 15, 20 or 30 nucleotides of SEQ ID NO: 17. Therefore Kupfer et al. anticipate claim 11 of the instant application as written.

Claims 1-14 lack an inventive step under PCT Article 33(3) as being obvious over Inoue et al. in view of Turco et al. Claims 1-14 are drawn to a purified protein having mannosidase activity comprising an amino acid sequence selected from the group consisting of a) SEQ ID NOs: 3, 6, and 18, b) a conservative (Continued on Supplemental Sheet.)

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

TIME LIMIT:

The time limit set for response to a Written Opinion may not be extended. 37 CFR 1.484(d). Any response received after the expiration of the time limit set in the Written Opinion will not be considered in preparing the International Preliminary Examination Report.

V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):

variant, or c) amino acid sequences having at least 60% sequence identity to the sequences specified in a) (claim 1), a binding agent (claim 2), an isolated nucleic acid encoding the same, vector, host cell, a method for altering glycosylation pattern of a macromolecule (claims 3-6, 8-10), a transgenic fungus (claim 7), an isolated nucleic acid comprising a sequence selected from the group consisting of at least 15 nucleotides of SEQ ID NO:1 (claim 11(a)), a method for altering glycosylation pattern (claim 12), a method for isolating nucleic acid sequence encoding a mannosidase and a mannosidase identified by the above method (claims 13-14). Inoue et al. disclose a mannosidase that more than 60% identical to SEQ ID NO:6 and also a nucleic acid sequence encoding such a mannosidase and wherein at least 15 nucleotides are identical to SEQ ID NO:1. However, the reference does not teach the production of a transgenic fungus or the glycosylation methods. Turco et al. teach the different methods of glycosylation using a mannosidase enzyme. It would have been obvious to one of ordinary skill in the art to combine the above two references with the high level of knowledge in the art of molecular biology to make a transgenic fungus comprising the above alpha-mannosidase and also to develop an assay to detect other mannosidases using the above polynucleotide sequences. One of ordinary skill in the art would have been motivated to do so as Inoue et al. provide a new alpha-mannosidase isolated from a industrially important fungus. One of skill in the art would have had a reasonable expectation of success since Inoue et al provide methods for all the above and also provide a nucleic acid sequence and an amino acid sequence of a alpha-mannosidase. therefore, the above invention would have been *prima facie* obvious to one of ordinary skill in the art.

Claims 2 and 7 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest a binding agent or a transgenic fungus for alpha-mannosidase.

----- NEW CITATIONS -----

Database GenBank Accession No. AA787675, (KUPFER et al.) An *Aspergillus nidulans* EST database, 31 July 1998.
Database Sptrembl_16 Accession No. Q12563, (INOUE et al.) Alpha mannosidase, 01 November 1996.

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

To: PAULA A. DE GRANDIS
KLARQUIST, SPARKMAN, CAMPBELL, LEIGH &
WHINSTON, LLP
ONE WORLD TRADE CENTER, SUITE 1600
121 SW SALMON STREET
PORTLAND, OR 97204

Date of Mailing
(day/month/year) **28 FEB 2001**

Applicant's or agent's file reference
2847-56232

FOR FURTHER ACTION See paragraphs 1 and 4 below

International application No.
PCT/US00/27210

International filing date
(day/month/year)
02 OCTOBER 2000

Applicant
UNIVERSITY OF VICTORIA INNOVATION AND DEVELOPMENT CORPORATION

1. ☒ The applicant is hereby notified that the international search report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 *bis* 1 and 90 *bis* 3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MANJUNATH RAO

Telephone No. (703) 305-3230

TERRY J. DEY
PARALEGAL SPECIALIST
TECHNOLOGY CENTER 1600

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 2847-56232	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US00/27210	International filing date (<i>day/month/year</i>) 02 OCTOBER 2000	(Earliest) Priority Date (<i>day/month/year</i>) 01 OCTOBER 1999
Applicant UNIVERSITY OF VICTORIA INNOVATION AND DEVELOPMENT CORPORATION		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☐ Certain claims were found unsearchable (See Box I).

3. ☒ Unity of invention is lacking (See Box II).

4. With regard to the title,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No. _____

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/27210

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/27210

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 9/00, 9/24, 15/09, 1/20; C07K 16/00

US CL : 435/69.2, 183, 200; 530/389.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.2, 183, 200; 530/389.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, CAPLUS, EMBASE, MEDLINE, SCISEARCH, USPTO WEST.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	HERSCOVIC ET AL. Isolation of a mouse golgi mannosidase cDNA, a member of a gene family conserved from yeasts to mammals. J. Biol. Chem. 01 April 1994, Vol. 269, No. 13, pages 9864-9871, see especially pages 9870-9871.	1, 3-14 ----- 1, 3-14
X --- Y	LAL ET AL. Isolation and expression of murine and rabbit cDNAs encoding an alpha-mannosidase involved in the processing of asparagine-linked oligosaccharides. J. Biol. Chem. 01 April 1994, Vol. 269, No. 13, pages 9872-9881, see entire article.	1, 3-14 ----- 1, 3-14
Y	TURCO ET AL. Altered G-protein glycosylation in vesicular stomatitis virus-infected glucose-deprived baby hamster kidney cells. J. Biol. Chem. 10 August 1982, Vol. 257, No. 15, pages 8674-8679, see entire article.	1, 3-14

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 JANUARY 2001

Date of mailing of the international search report

28 FEB 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MANJUNATH RAO

Telephone No. (703) 308-0196

TERRY J. DEY
PARALEGAL SPECIALIST
TECHNOLOGY CENTER 1600

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/27210

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 5,837,836 A (FRIDERICI ET AL.) 17 November 1998 (17/11/98) see entire document.	2 --- 2
X --- Y	US 5,578,484 A (HOROSZEWICZ) 26 November 1996 (26/11/96) see entire document.	2 --- 2
X --- Y	EADES ET AL. Identification and analysis of a class 2 alpha- mannosidase from Aspergillus nidulans. Glycobiology. 1998, Vol. 8, pages 17-33, see entire document.	1-14 --- 1-14
X --- Y	INOUE ET AL. Molecular cloning and nucleotide sequence of the 1,2-alpha-D-mannosidase gene, msds, from Aspergillus saitoi and expression of the gene in yeast cells. Biochimica et Biophysica Acta. 1995, Vol. 1253, pages 141-145, see entire document.	1-14 --- 1-14

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1, 3-7, 11, 13-14, drawn to a purified mannosidase, polynucleotides and method of making.

Group II, claim 2, drawn to a binding agent that binds the purified protein.

Group III, claims 8-10 and 12, drawn to a method of altering glycosylation pattern of a macromolecule.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Mannosidases, their polynucleotides, binding agents and method of altering the glycosylation pattern of macromolecules are well known in the prior art. Thus, the above invention, when considered as a whole does not contribute over the prior art (see Turco et al. J. Biol. Chem., 1982, Vol. 257(15):8674-8679).

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number
WO 01/25406 A1

(51) International Patent Classification⁷: C12N 9/00,
9/24, 15/09, 1/20, C07K 16/00

(21) International Application Number: PCT/US00/27210

(22) International Filing Date: 2 October 2000 (02.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/157,341 1 October 1999 (01.10.1999) US

(71) Applicant (for all designated States except US): UNI-
VERSITY OF VICTORIA INNOVATION & DEVELOPMENT CORPORATION [CA/CA]; Box 3075 R-Hut,
McKenzie Avenue, Victoria, British Columbia V8W 3W2 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HINTZ, William, E.
[CA/CA]; 5601 Matterhorn Court, Victoria, British Columbia V9E 2G1 (CA). EADES, Caleb, Joshua [US/CA]; 852
Leslie Drive, Victoria, British Columbia V8X 2Y4 (CA).

(74) Agent: DE GRANDIS, Paula, A.; Klarquist, Sparkman,
Campbell, Leigh & Winston, LLP, Suite 1600, One World
Trade Center, 121 S.W. Salmon Street, Portland, OR 97204 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MANNOSIDASES AND METHODS FOR USING SAME

(57) Abstract: Mannosidase enzymes and use of such enzymes to alter the glycosylation patterns of macromolecules are disclosed. Also disclosed are the nucleic acid sequences encoding the mannosidase enzymes.

WO 01/25406 A1

10 REC'D 25 MAR 2002

SEQUENCE LISTING

<110> Hintz, William et al.

<120> Mannosidases and Methods for using the Same

<130> 56232

<140>

<141>

<150> 60/157,341

<151> 1999-10-01

<160> 19

<170> PatentIn Ver. 2.0

<210> 1

<211> 3328

<212> DNA

<213> Aspergillus nidulans

<400> 1

```

aggggcctttt caggggcttg ttggccaaac ctgccgtatt ttcgattcag ggcgggccct 60
taattctggg gaccgatatc ccttgaacgc gggggcaatc agttcaacca acccagaccg 120
ctgggcttg tatgagattg cgagcatcta tgtcggtgta ccttctgaat gacaatgaat 180
gtattttact tctcgaaaag aacccttggg cactgaattg tgcggagaat gatgccctga 240
ttatgatata actagtccgc tccgtcaagc cacaagggtc tgggcagtc gctataaatc 300
aaaatcgct gcacgaacag acgaataacc aagaaaaacgc ccgagcgcga gcgtttcttc 360
ttcctctaag ccttgcagct ggctctgcgt ctttgatcaa ccctttagct gaatttcccc 420
agaacttcag ccctctgcat cctgtcctta ccgcaactcg ttaacctgcg cgacctcgcg 480
cgaccacagc cttaggtttc gagatgccat gaaaatcaga aattgaaccc cctttccatt 540
actatcattc tctgcattct gcgagtgate tgtccttoga cgttcccttc ttcacagcgt 600
gcggcgccct cactctcgtt gcctacgttt gaccacggtc ctacctctcc tactgctgat 660
tattaggctc ctccctacgc ctccaatata ggggaagtgc cggccatggt tegtgcacga 720
cgatctcgca tctcgtctgt gtttgccgtt atatttgctc tctcatatt ccactttagc 780
cgtctcgag ttacgatcag cctgcaatct tgggtacctc cgcgcgccgt cgatccaccat 840
aatccccctt tccccgacca gaacctcaaa gatccatacg aaaacgacaa tagtgcgacc 900
ggcagtgggg ctccctccgc tgcgttggta gagccagaag aataccaacg accaccactt 960
tacacagatt cagatgacag cccaactccg tcaaaaagaac gcctggacac cccgagcaat 1020
gtcccatctc aggagcctga atttgatgc gccagacttc agacgggtgc gcagacccaa 1080
aataaacatg aagatgatga ggatattgtc ccaatttctc actggaagcc gatgcccga 1140
cggcatccag tcagtccgga ggctttgatc aagctgccaa ccgggcaatc aaaggaaactc 1200
ccccaactgc aagctaagtt caaggacgag tegtctcgg acaagatgca gcggctgcaa 1260
caacttgaca ctatcaagtc ggcgttctta catgcgtgga acggttacaa gatctctgcc 1320
atgggtcatg atgaggttag acctctgcgc ggtggtttca aggacacatt caatggctgg 1380
ggcgcgaccc ttgtcgacgc cttggatacc ctgtggatca tggatctcaa agaggagttc 1440
tccatggcag tcgactacgt caagaaaatc gattttacca ccagcaccaa gaaagagatt 1500
ccggtctttg aaaccactat tegtaccta ggcgggatgc tcggggccta tgatatttcg 1560
ggacacaaat acgatatact tttggaaaag tctgttgagc ttgcggatgt cttgatggac 1620
gccttcgaca caccgaaccg gatgccaacc ctctattata aatggagccc agagtatgct 1680
tcagagtttc gccgggggga ctttaaggct gttctcgccg agcttggtc tctctctctc 1740
gagttcacgc gtttggcgca gttgacaaaa caggacaagt actacgatgc aattgcacga 1800
atcacaaatg agctcgaaaa gtatcaggat ttgacaaagc ttcccggctt gtggcctctc 1860
aacctggacg catccgggtg caggcgagtt cccggcgtct cgcgagagcc tgcctcggtc 1920
gggcagccag tcagatggtc ctctgacgag atcaactcga cgagctcggt atcgatctgt 1980
acaagacaaa ttcagtgggg cggagagcct gtccgtcatg acaatgattc gtttgaaacg 2040
ggttttcctg tatcagtcga tactcggact cctcccccaa agcaagattg caccggaggc 2100
ctcaacgatc agctctcagg cattgacaag ttcggactcg gagcccttgg tgactctacg 2160
tacgagtact taccgaaaga gtatatgttg ctccggcgta acaacgacca gtacctcaac 2220

```

atgtatcaga	aggccatgga	cacagtgcga	gaatatcttg	tttatcagcc	aatgctcaag	2280
aataatcgcg	atgtccgctt	cttagcgaca	gttagtatga	caaagagcct	tgatgcaaac	2340
cctccggggc	gtaccacttt	cgcgtagcaa	ggcactcacc	tcacctgttt	tgctggtggt	2400
atgcttgcca	ttggcgccaa	gttggttggt	cttgataagg	atctaaagct	gggtagtcaa	2460
ctgacggacg	gctgtgtctg	ggcatatgaa	gccacaaagt	ccggaatcat	gccggaagca	2520
ttccaactgg	tcccttgtaa	gaaaggcgag	ccatgcgaat	gggatgagga	cgcatactac	2580
atggccatgg	atccttatgc	cgacaagcgg	ccaatatcac	ataacaaacg	ctccgcccggc	2640
cctgaaaagg	ggaattggca	cgctgtcgcc	acagccgaat	cgtcttcgcc	ccaggaagat	2700
aaaacacaga	aatcaaccac	tactgagggt	cgacacaccg	gtacaactac	cggggtcaggc	2760
gcgctctcgc	acgaggaatt	cgtcacggga	aaaatcctca	acgaccgact	cccgcggggc	2820
atgacaggga	tctcggtctg	gcagtacctc	cttcgcccgg	aggcgatcga	gtctgtcttc	2880
atcatgttcc	gcctcacggg	cgatccttcc	tggcgcgaaa	agggttgga	gatgttccag	2940
gctgtcgaca	aagccacgaa	gacggagctg	gcgaactcgg	ccatttccga	cgtaaccgtc	3000
gataatccac	gcccgggtgga	cagtatggaa	tcattctggc	ttgcgagagc	tctgaaatac	3060
ttctaccttc	ttttcagcga	tccaagcctg	gtgagccttg	acgaatatgt	cttgtaagtg	3120
atgcttgact	taatcgactg	cttgatgctg	acttttccct	taggaacacc	gagggtcatc	3180
cgttcaagcg	acccaagtac	tgaagtacta	atttaaataga	tcttttagcc	tgratctata	3240
catggccgct	ccgctgtaga	agcattgata	ccattaagac	agtatcgctg	cattcgtgta	3300
ccatttgagc	ttccagagga	acctcttt				3328

<210> 2

<211> 2448

<212> DNA

<213> *Aspergillus nidulans*

<400> 2

atgtttcgtg	cacgacgac	tgcgcatctg	ctggtgtttg	ccgttatatt	tgtccctctc	60
atattccact	ttagccgtct	cgcagttacg	atcagcctgc	aatcttgggt	acctccgccc	120
cccgctcgatc	accataatcc	ccctttcccc	gaccagaacc	tcaaagatcc	atacgaatac	180
gacaatagtg	cgaccggcag	tggggctcct	ccgcctgcgt	tggtagagcc	agaagaatac	240
caacgaccac	cactttacac	agattcagat	gacagcccaa	ctccgtcaaa	agaacgcctg	300
gacaccccca	gcaatgtccc	atctcaggag	cctgaatttg	atgccgccag	acttcagacg	360
ggtgctgcaga	cccaaaataa	acatgaagat	gatgaggata	ttgtcccaat	ttctcactgg	420
aagccgatgc	ccgaacggca	tccagtcagt	ccggaggctt	tgatcaagct	gccaaccggg	480
caatcaaaag	aactccccca	actgcaagct	aagttcaagg	acgagtcgtc	ctcggacaag	540
atgcagcggc	tgcaacaact	tgacactatc	aagtcggcgt	tcttacatgc	gtggaacggg	600
tacaagatct	ctgccatggg	tcatgatgag	gttagacctc	tgcgcgggtg	tttcaaggac	660
acattcaatg	gctggggcgc	gacctttgtc	gacgccttgg	ataccctgtg	gatcatggat	720
ctcaaagagg	agttctccat	ggcagtcgac	tacgtcaaga	aaatcgattt	taccaccagc	780
accaagaaag	agattccggg	ctttgaaacc	actattcgct	acctaggcgg	gatgctcggg	840
gcctatgata	tttcgggaca	caaatacga	atacttttgg	aaaagtctgt	tgagcttgcg	900
gatgtcctga	tggagcgctt	cgacacaccg	aaccggatgc	caacctctta	ttataaatgg	960
agcccagagt	atgcttcaga	gtttcgccgg	ggggacttta	aggctgttct	cgcggagctt	1020
ggctctctct	ctctcgagtt	cacgcgtttg	gcgcagttga	ccaaacagga	caagtactac	1080
gatgcaattg	cacgaatcac	aaatgagctc	gaaaagtatc	aggatttgac	aaagcttccc	1140
ggcttgtggc	ctctcaacct	ggacgcaccc	gggtgcaggc	gagttcccgg	cgtctcgcga	1200
gagcctgctg	cggttgggca	gccagtcaga	tggctcctctg	acgagatcaa	ctcgacgagc	1260
tcggtatcgt	atcgtacaag	acaaattcat	gagggcggag	agcctgtccg	tcatgacaa	1320
gattcgtttg	aaacgggttt	tctgtatca	gtcgatactc	ggactcctcc	cccaaagcaa	1380
gattgcaccg	gaggcctcaa	cgatcagctc	tcaggcattg	acaagtccgg	actcggagcc	1440
cttggtgact	ctacgtacga	gtacttaccg	aaagagtata	tggtgtctcg	cggtaacaac	1500
gaccagtacc	tcaacatgta	tcagaaggcc	atggacacag	tgcgagaata	tcttgtttat	1560
cagccaatgc	tcaagaataa	tcgcgargtc	cgcttcttag	cgacagttag	tatgacaaag	1620
agccttgatg	cnaaacctcc	ggggcggtacc	actttcgcgt	acgaaggcac	tcacctcacc	1680
tgttttgctg	gtggtatgct	tgccattggc	gccaaagtgt	ttgggcttga	taaggatcta	1740
aagctgggta	gtcaactgac	ggacggctgt	gtctgggcat	atgaagccac	aaagtccgga	1800
atcatgccgg	actggctcca	actggctcct	tgtgaagaaag	gcgagccatg	cgaatgggat	1860
gaggacgcat	actacatggc	catggatcct	tatgccgaca	agcggccaat	atcacataac	1920
aaacgctccg	ccggccctga	aaaggggaat	tggcacgtcg	tcgccacagc	cgaatcgtct	1980
tcgccccagg	aagataaaac	acagaaatca	accactactg	agggtcgaca	caccgggtaca	2040

```

actaccgggg caggcgcgct ctcgcacgag gaattcgtca cgggaaaaat cctcaacgac 2100
cgactcccg cgggcatgac agggatctcg gctcggcagt acctccttcg cccggaggcg 2160
atcgagtctg tcttcatcat gtccgcctc acgggcgatc cttcctggcg cgaaaagggg 2220
tggaagatgt tccaggctgt cgacaaagcc acgaagacgg agctggcgaa ctccggccatt 2280
tccgacgtaa ccgtcgataa tccacgcccg gtggacagta tggaatcatt ctggccttgcg 2340
gagactctga aatacttcta cttcttttc agcgatccaa gcctgggtgag ccttgaggaa 2400
tatgtcttga acaccgaggc tcatccgttc aagcgaccca ggtactga 2448

```

<210> 3
 <211> 815
 <212> PRT
 <213> Aspergillus nidulans

<400> 3

```

Met Phe Arg Ala Arg Arg Ser Arg Ile Ser Leu Val Phe Ala Val Ile
  1             5             10             15

```

```

Phe Val Leu Leu Ile Phe His Phe Ser Arg Leu Ala Val Thr Ile Ser
      20             25             30

```

```

Leu Gln Ser Trp Val Pro Pro Pro Pro Val Asp His His Asn Pro Pro
      35             40             45

```

```

Phe Pro Asp Gln Asn Leu Lys Asp Pro Tyr Glu Asn Asp Asn Ser Ala
      50             55             60

```

```

Thr Gly Ser Gly Ala Pro Pro Pro Ala Leu Val Glu Pro Glu Glu Tyr
      65             70             75             80

```

```

Gln Arg Pro Pro Leu Tyr Thr Asp Ser Asp Asp Ser Pro Thr Pro Ser
      85             90             95

```

```

Lys Glu Arg Leu Asp Thr Pro Ser Asn Val Pro Ser Gln Glu Pro Glu
      100            105            110

```

```

Phe Asp Ala Ala Arg Leu Gln Thr Gly Ala Gln Thr Gln Asn Lys His
      115            120            125

```

```

Glu Asp Asp Glu Asp Ile Val Pro Ile Ser His Trp Lys Pro Met Pro
      130            135            140

```

```

Glu Arg His Pro Val Ser Pro Glu Ala Leu Ile Lys Leu Pro Thr Gly
      145            150            155            160

```

```

Gln Ser Lys Glu Leu Pro Gln Leu Gln Ala Lys Phe Lys Asp Glu Ser
      165            170            175

```

```

Ser Ser Asp Lys Met Gln Arg Leu Gln Gln Leu Asp Thr Ile Lys Ser
      180            185            190

```

```

Ala Phe Leu His Ala Trp Asn Gly Tyr Lys Ile Ser Ala Met Gly His
      195            200            205

```

```

Asp Glu Val Arg Pro Leu Arg Gly Gly Phe Lys Asp Thr Phe Asn Gly
      210            215            220

```

```

Trp Gly Ala Thr Leu Val Asp Ala Leu Asp Thr Leu Trp Ile Met Asp
      225            230            235            240

```

```

Leu Lys Glu Glu Phe Ser Met Ala Val Asp Tyr Val Lys Lys Ile Asp
      245            250            255

```

Phe Thr Thr Ser Thr Lys Lys Glu Ile Pro Val Phe Glu Thr Thr Ile
 260 265 270
 Arg Tyr Leu Gly Gly Met Leu Gly Ala Tyr Asp Ile Ser Gly His Lys
 275 280 285
 Tyr Asp Ile Leu Leu Glu Lys Ser Val Glu Leu Ala Asp Val Leu Met
 290 295 300
 Asp Ala Phe Asp Thr Pro Asn Arg Met Pro Thr Leu Tyr Tyr Lys Trp
 305 310 315 320
 Ser Pro Glu Tyr Ala Ser Glu Phe Arg Arg Gly Asp Phe Lys Ala Val
 325 330 335
 Leu Ala Glu Leu Gly Ser Leu Ser Leu Glu Phe Thr Arg Leu Ala Gln
 340 345 350
 Leu Thr Lys Gln Asp Lys Tyr Tyr Asp Ala Ile Ala Arg Ile Thr Asn
 355 360 365
 Glu Leu Glu Lys Tyr Gln Asp Leu Thr Lys Leu Pro Gly Leu Trp Pro
 370 375 380
 Leu Asn Leu Asp Ala Ser Gly Cys Arg Arg Val Pro Gly Val Ser Arg
 385 390 395 400
 Glu Pro Ala Ala Ala Gly Gln Pro Val Arg Trp Ser Ser Asp Glu Ile
 405 410 415
 Asn Ser Thr Ser Ser Val Ser Tyr Arg Thr Arg Gln Ile His Glu Gly
 420 425 430
 Gly Glu Pro Val Arg His Asp Asn Asp Ser Phe Glu Thr Gly Phe Pro
 435 440 445
 Val Ser Val Asp Thr Arg Thr Pro Pro Pro Lys Gln Asp Cys Thr Gly
 450 455 460
 Gly Leu Asn Asp Gln Leu Ser Gly Ile Asp Lys Phe Gly Leu Gly Ala
 465 470 475 480
 Leu Gly Asp Ser Thr Tyr Glu Tyr Leu Pro Lys Glu Tyr Met Leu Leu
 485 490 495
 Gly Gly Asn Asn Asp Gln Tyr Leu Asn Met Tyr Gln Lys Ala Met Asp
 500 505 510
 Thr Val Arg Glu Tyr Leu Val Tyr Gln Pro Met Leu Lys Asn Asn Arg
 515 520 525
 Asp Val Arg Phe Leu Ala Thr Val Ser Met Thr Lys Ser Leu Asp Ala
 530 535 540
 Asn Pro Pro Gly Arg Thr Phe Ala Tyr Glu Gly Thr His Leu Thr
 545 550 555 560
 Cys Phe Ala Gly Gly Met Leu Ala Ile Gly Ala Lys Leu Phe Gly Leu
 565 570 575

Asp Lys Asp Leu Lys Leu Gly Ser Gln Leu Thr Asp Gly Cys Val Trp
 580 585 590
 Ala Tyr Glu Ala Thr Lys Ser Gly Ile Met Pro Glu Ala Phe Gln Leu
 595 600 605
 Val Pro Cys Lys Lys Gly Glu Pro Cys Glu Trp Asp Glu Asp Ala Tyr
 610 615 620
 Tyr Met Ala Met Asp Pro Tyr Ala Asp Lys Arg Pro Ile Ser His Asn
 625 630 635 640
 Lys Arg Ser Ala Gly Pro Glu Lys Gly Asn Trp His Val Val Ala Thr
 645 650 655
 Ala Glu Ser Ser Ser Pro Gln Glu Asp Lys Thr Gln Lys Ser Thr Thr
 660 665 670
 Thr Glu Gly Arg His Thr Gly Thr Thr Thr Gly Ala Gly Ala Leu Ser
 675 680 685
 His Glu Glu Phe Val Thr Gly Lys Ile Leu Asn Asp Arg Leu Pro Pro
 690 695 700
 Gly Met Thr Gly Ile Ser Ala Arg Gln Tyr Leu Leu Arg Pro Glu Ala
 705 710 715 720
 Ile Glu Ser Val Phe Ile Met Phe Arg Leu Thr Gly Asp Pro Ser Trp
 725 730 735
 Arg Glu Lys Gly Trp Lys Met Phe Gln Ala Val Asp Lys Ala Thr Lys
 740 745 750
 Thr Glu Leu Ala Asn Ser Ala Ile Ser Asp Val Thr Val Asp Asn Pro
 755 760 765
 Arg Pro Val Asp Ser Met Glu Ser Phe Trp Leu Ala Glu Thr Leu Lys
 770 775 780
 Tyr Phe Tyr Leu Leu Phe Ser Asp Pro Ser Leu Val Ser Leu Glu Glu
 785 790 795 800
 Tyr Val Leu Asn Thr Glu Ala His Pro Phe Lys Arg Pro Arg Tyr
 805 810 815

<210> 4

<211> 2177

<212> DNA

<213> *Aspergillus nidulans*

<400> 4

cggaatgtgc ctaaagtggg aggtatgatg atgcccagga tcgcgccccca gtcatacaact 60
 ccatacatggg acggtccttg atcctcaagg cacgaagtgg agatcaggtc cgtagtgcac 120
 atgcatggcc catcagcctg aagcacttcc ccaagcaaag tcgagactcg gacaccgatg 180
 atatccctgc tgcctctgac tgatgcatag tgcattgccc tgcgttggtt ccccttttca 240
 ctccgcctgg tctccagtct ccactcctca ccattgatgt ctgccccgcg ccgccctcca 300
 tcctccatca ttcttatatc tacggactcg gtcactcggt atcactagag tccttggtta 360
 ttcttagtgt ttgcattctt acgtgtagtt atgcgtacgc ttctcgctct cgcggccttc 420
 gcgggctttg ccgctgctag ggtgcccgcc tacgccatca cgcgcccggg gatgcgcagt 480
 gattctcgcg ccgacgctgt caaggaggcc ttttcgcatg cctgggacgg ttactacaac 540

```

tacgcttttc ctcacgacga gcttcacccg atttcgaacg gttacggaga ctccgcgaaac 600
cactggggcg cgtcggccgt cgacgctcta tcgacggcca tcatgatgcg caacgcgacc 660
atcgtcaacc agatccttga ccatattgct gctgtggact actccaagac caacgccatg 720
gtaagtgtgt tcgagacgac catccggtac ctccgcgggca tgatttctgg atacgacctg 780
ctcaaaggcc ctgcccgggg gttgggtggac gacagcaggg tcgacgtgct tctagagcag 840
tcgcagaacc tcgcccagggt gctgaaattc gcgttcgaca ctcttcttgg tgtgccgtac 900
aacatgatta acattacttc gggcggcaac gacggcgcca cgaccaacgg gctggccgtg 960
accggtacct tgggtgctgga gtggacgcgt ctgtcggact tgactgggaa cgacgagtat 1020
gcccgcttga gccagagagc tgaagactac ctctccacc cggagccagc gcagtacgaa 1080
ccgttccctg gattgattgg aagcgcagtc aatattgccg acggcaagct cgccaatggg 1140
cacatcagct ggaatgggtg cgcagactcg tactacgagt acctgatcaa gatgtacgtc 1200
tacgatcccg aacgcttttg cctctaccgg gaccgctggg tcgcagctgc cgagtcgagc 1260
atcaaccatc tggcttcgca cccgtccacc cgcccagacg tgactttctt ggccacttac 1320
aacgaggagc atcagctggg cctgaccagc caacacctga cctgcttcga cgggtggaagc 1380
tttctgcttg gtgggacatt gctggaccgc caggactttg tcgacttcgg ccttgacctt 1440
gtcgccggct gccacgagac gtacaactcg actctgacgg gcatcggcc tgagcaattc 1500
agctgggacc ctaacgggtg gcccgacagc cagaaggagc tgttcgagcg cgcaggcttc 1560
tacatcaaca gcggccaata cattcttcgt cccgaagtca tcgagagctt ctactatgca 1620
tggcgcgtca caggtgatgg aacggtacgt tcaactcagc ctgcttccgt aggaagacca 1680
tactgaccgc tttagtacct cgaatgggtg tggaaacgct tcaccaacat caacaagtac 1740
tgccgcacct cgacgggttt cgcggggctg gagaacgtca atgcagcgaa cggcggaggc 1800
cggatcgaca accaggagag tttcatgttc gcagaggtgc tgaagtattc gtttttgact 1860
tttgcctctg gtacgttttc ctagtcttgg ttacactgtg gagaatatta ctgactgcag 1920
cagaggacga ctggcaggtg cagaagggca gtggaaatac gtttgtttat aacaccgagg 1980
cgcaccgctt taaggtgtat acgcctcagt agatagtaca tattgtgctc tagcgtactg 2040
catgcataac ctaaattggc tcacctactt actgactact ctactgacaa gcagttgcct 2100
ttatatgtct ttaaggagct tgggcggtaa atcgtaattc actctaaact ccgctgtctg 2160
ttcggggaag gctgggc 2177

```

<210> 5

<211> 1515

<212> DNA

<213> *Aspergillus nidulans*

<400> 5

```

atgcgtacgc ttctcgtctt cgcggccttc gcgggctttg ccgctgctag ggtgcccgcc 60
tacgccatca cgcgcccggg gatgcgcagt gattctcgcg ccgacgctgt caaggaggcc 120
ttttcgcatt cctgggacgg ttactacaac tacgcttttc ctcacgacga gcttcacccg 180
atttcgaacg gttacggaga ctccgcgaaac cactggggcg cgtcggccgt cgacgctcta 240
tcgacggcca tcatgatgcg caacgcgacc atcgtcaacc agatccttga ccatattgct 300
gctgtggact actccaagac caacgccatg gtaagtgtgt tcgagacgac catccggtac 360
ctcgcgggca tgatttctgg atacgacctg ctcaaaggcc ctgcccgggg gttggtggac 420
gacagcaggg tcgacgtgct tctagagcag tcgcagaacc tcgcccagggt gctgaaattc 480
gcgttcgaca ctcttcttgg tgtgccgtac aacatgatta acattacttc gggcggcaac 540
gacggcgcca cgaccaacgg gctggccgtg accggtacct tgggtgctgga gtggacgcgt 600
ctgtcggact tgactgggaa cgacgagtat gccgcttga gccagagagc tgaagactac 660
cttctccacc cggagccagc gcagtacgaa ccgttccctg gattgattgg aagcgcagtc 720
aatattgccg acggcaagct cgccaatggg cacatcagct ggaatgggtg cgcagactcg 780
tactacgagt acctgatcaa gatgtacgtc tacgatcccg aacgctttgg cctctaccgg 840
gaccgctggg tcgcagctgc cgagtcgagc atcaaccatc tggcttcgca cccgtccacc 900
cgcccagacg tgactttctt ggccacttac aacgaggagc atcagctggg cctgaccagc 960
caacacctga cctgcttcga cgggtggaagc tttctgcttg gtgggacatt gctggaccgc 1020
caggactttg tcgacttcgg ccttgacctt gtcgcccggc gccacgagac gtacaactcg 1080
actctgacgg gcatcgcccc tgagcaattc agctgggacc ctaacgggtg gcccgacagc 1140
cagaaggagc tgttcgagcg cgcaggcttc tacatcaaca gcggccaata cattcttcgt 1200
cccgaagtca tcgagagctt ctactatgca tggcgcgtca caggtgatgg aacgtacctc 1260
gaatgggtgt ggaacgcctt caccaacatc aacaagtact gccgcactgc gaccggtttc 1320
gcggggctgg agaacgtcaa tgcagcgaac ggcggaggcc ggatcgacaa ccaggagagt 1380
ttcatgttcg cagaggtgct gaagtattcg tttttgactt ttgctcctga ggacgactgg 1440
caggtgcaga agggcagtggt aaatacgttt gtttataaca ccgaggcgca cccgtttaag 1500
gtgtatacgc ctcag 1515

```

<210> 6
 <211> 505
 <212> PRT
 <213> Aspergillus nidulans

<400> 6
 Met Arg Thr Leu Leu Ala Leu Ala Ala Phe Ala Gly Phe Ala Ala Ala
 1 5 10 15
 Arg Val Pro Ala Tyr Ala Ile Thr Arg Pro Val Met Arg Ser Asp Ser
 20 25 30
 Arg Ala Asp Ala Val Lys Glu Ala Phe Ser His Ala Trp Asp Gly Tyr
 35 40 45
 Tyr Asn Tyr Ala Phe Pro His Asp Glu Leu His Pro Ile Ser Asn Gly
 50 55 60
 Tyr Gly Asp Ser Arg Asn His Trp Gly Ala Ser Ala Val Asp Ala Leu
 65 70 75 80
 Ser Thr Ala Ile Met Met Arg Asn Ala Thr Ile Val Asn Gln Ile Leu
 85 90 95
 Asp His Ile Ala Ala Val Asp Tyr Ser Lys Thr Asn Ala Met Val Ser
 100 105 110
 Leu Phe Glu Thr Thr Ile Arg Tyr Leu Ala Gly Met Ile Ser Gly Tyr
 115 120 125
 Asp Leu Leu Lys Gly Pro Ala Ala Gly Leu Val Asp Asp Ser Arg Val
 130 135 140
 Asp Val Leu Leu Glu Gln Ser Gln Asn Leu Ala Glu Val Leu Lys Phe
 145 150 155 160
 Ala Phe Asp Thr Pro Ser Gly Val Pro Tyr Asn Met Ile Asn Ile Thr
 165 170 175
 Ser Gly Gly Asn Asp Gly Ala Thr Thr Asn Gly Leu Ala Val Thr Gly
 180 185 190
 Thr Leu Val Leu Glu Trp Thr Arg Leu Ser Asp Leu Thr Gly Asn Asp
 195 200 205
 Glu Tyr Ala Arg Leu Ser Gln Arg Ala Glu Asp Tyr Leu Leu His Pro
 210 215 220
 Glu Pro Ala Gln Tyr Glu Pro Phe Pro Gly Leu Ile Gly Ser Ala Val
 225 230 235 240
 Asn Ile Ala Asp Gly Lys Leu Ala Asn Gly His Ile Ser Trp Asn Gly
 245 250 255
 Gly Ala Asp Ser Tyr Tyr Glu Tyr Leu Ile Lys Met Tyr Val Tyr Asp
 260 265 270
 Pro Glu Arg Phe Gly Leu Tyr Arg Asp Arg Trp Val Ala Ala Ala Glu
 275 280 285

Ser Ser Ile Asn His Leu Ala Ser His Pro Ser Thr Arg Pro Asp Val
 290 295 300
 Thr Phe Leu Ala Thr Tyr Asn Glu Glu His Gln Leu Gly Leu Thr Ser
 305 310 315 320
 Gln His Leu Thr Cys Phe Asp Gly Gly Ser Phe Leu Leu Gly Gly Thr
 325 330 335
 Leu Leu Asp Arg Gln Asp Phe Val Asp Phe Gly Leu Asp Leu Val Ala
 340 345 350
 Gly Cys His Glu Thr Tyr Asn Ser Thr Leu Thr Gly Ile Gly Pro Glu
 355 360 365
 Gln Phe Ser Trp Asp Pro Asn Gly Val Pro Asp Ser Gln Lys Glu Leu
 370 375 380
 Phe Glu Arg Ala Gly Phe Tyr Ile Asn Ser Gly Gln Tyr Ile Leu Arg
 385 390 395 400
 Pro Glu Val Ile Glu Ser Phe Tyr Tyr Ala Trp Arg Val Thr Gly Asp
 405 410 415
 Gly Thr Tyr Leu Glu Trp Val Trp Asn Ala Phe Thr Asn Ile Asn Lys
 420 425 430
 Tyr Cys Arg Thr Ala Thr Gly Phe Ala Gly Leu Glu Asn Val Asn Ala
 435 440 445
 Ala Asn Gly Gly Gly Arg Ile Asp Asn Gln Glu Ser Phe Met Phe Ala
 450 455 460
 Glu Val Leu Lys Tyr Ser Phe Leu Thr Phe Ala Pro Glu Asp Asp Trp
 465 470 475 480
 Gln Val Gln Lys Gly Ser Gly Asn Thr Phe Val Tyr Asn Thr Glu Ala
 485 490 495
 His Pro Phe Lys Val Tyr Thr Pro Gln
 500 505

<210> 7
 <211> 6
 <212> DNA
 <213> Aspergillus nidulans

<400> 7
 gtaagt

6

<210> 8
 <211> 6
 <212> DNA
 <213> Aspergillus nidulans

<400> 8
 gtangt

6

<210> 9
 <211> 6

<212> DNA
 <213> Aspergillus nidulans

<400> 9
 gctgac 6

<210> 10
 <211> 6
 <212> DNA
 <213> Aspergillus nidulans

<400> 10
 rctrac 6

<210> 11
 <211> 6
 <212> DNA
 <213> Aspergillus nidulans

<400> 11
 gtacgt 6

<210> 12
 <211> 6
 <212> DNA
 <213> Aspergillus nidulans

<400> 12
 actgac 6

<210> 13
 <211> 10
 <212> PRT
 <213> Aspergillus nidulans

<400> 13
 Gly Gly Leu Gly Glu Ser Phe Tyr Glu Tyr
 1 5 10

<210> 14
 <211> 9
 <212> PRT
 <213> Aspergillus nidulans

<400> 14
 Leu Ala Glu Thr Leu Lys Tyr Leu Tyr
 1 5

<210> 15
 <211> 29
 <212> DNA
 <213> PCR primer

<220> y represents c, t, or u; r represents g or a; n represents a, c, g, t, or u; and h represents a, c, t, or u

<400> 15
 ggyggcyctng gygartcntt ctacgagta 29

<210> 16
 <211> 32
 <212> DNA
 <213> PCR primer

<220> y represents c, t, or u; r represents g or a; n represents a, c, g, t, or u; and h represents a, c, t, or u

<400> 16
 gtanaggtac ttanagngtct cngcnagriha gaa

33

<210> 17
 <211> 2032
 <212> DNA
 <213> *Aspergillus nidulans*

<400> 17
 atcgatgtct gctgcataaa ggcagacgga ggaagatgcc gagacggtgg tcctccctca 60
 tcagcatcac agccatcttc ttggtcctct tcttcctcct tcataggaat acagacacac 120
 cagcgccgc caatagggct acaaacggcc ctgccaacgg ctttgctagg cagcaaagca 180
 tatgtccatc aacaccccct cagcctccat ataaccgaac cagcacggga gggttcaact 240
 ggggtgaaat ccagtcaga taccctgtat ccgacttcat cccgctgtca accaactctc 300
 ctgcaacact tccgcgcac caacgctctt ccttcccact tcaatcctca atcactaaat 360
 cccgccaggc agcagtcaaa ggtgcctttc agcgcgcacg gacctcctac acaaccacg 420
 cctggaaggc ggacgaggtta cggcccatca cggccggatc tcgaaacaac tttggcggat 480
 ggggagcgac cctagtcgac aatctcgaca cactgctaata catggggctg gacgaggagt 540
 tcgcagcggc agtcgacgag ctgcagata tagaattcag cccgcactcg tccccatcct 600
 cctcccagag cacaatcaac atattcgaaa cgacaatccg gtatctgggc ggcttgctcg 660
 cggcgatgta tctcactggc tgtcgagaga ctgcgctgct ggacaaagca atccagcttg 720
 gggagatgat ctacacctcc ttcgacacag agaaccgcac gcccgtagca cgggtggaatc 780
 tgcacaaagc aggaacgga gaggctcagc gcgcggcagc gcaggggcgtg ctgcgtgaac 840
 tcgccagcag cagtctcgag ttcaacgcggc tgtcgcagct gacgggggat atgcggtatt 900
 tcgatgcggc atcccgcat accgatctgc ttgactccca agccggccat acccggtacc 960
 cgggggttggt gccagtcagc gtgaacctgc agaaaggcga tctgacctgt gggtcgacat 1020
 tcagttttgg cgggatggcc gatagcgctt acgagtatct cggcaagacg tatcggtccc 1080
 tcgggtggtg ggggaaagg ccacagtacg agcgtctggc gcgaaacgca ctatagtcgg 1140
 ggattcgaca tctcctcttc cgaccgatga cgcctgatca tgcagatata ctctaccgc 1200
 gggtcgcgca cgcaaccagc tcttccgtgg gactcgagcc ccggacagag catctcgctt 1260
 gttttgtggg tgggatgtac gcgctcgccg ggaagctttt ctcaaaccag acgtacctcg 1320
 acaccggccg gaagctgaca gacggttgta tctggtacta cgataattca ccgctaggta 1380
 tcatgcccga gatgttcacc gtgccggcct gtccgtcagt ggctgaatgt ccttgggacg 1440
 aaacaagggg tggatatctac acctacgtgc gtgatgggca ctactttctg cgtcctgagg 1500
 caatggagag tatcttctat atgtggcgca ttacagggga cgaaaagtac cgcgaggctg 1560
 catggagaat gttcacggct atcgaagcgg ttacaaagac ggagtttggg aatgcggcgg 1620
 tgcgggatgt tatggttgag gaaggaaatg taaagagaga agatagcatg gagagtttct 1680
 ggatggcaga gacgttgaag tatctgtatc tgatatattg ggagaccgat ttggtcagct 1740
 tggacgactg ggtgttcaat accgagggcg accctttgag ggggtgcagg agttgacatt 1800
 gtattcacac atcggtatag acaaattata gagtagacgt tcaaaacggc caaaactgaa 1860
 tggatagact ccatatgcat tgaatatata atgtattcgc tgcaaaagcat ggataaaaata 1920
 aagatgtaca aagtgtcttt gttgtcgctt tgaaagtggg atatcatccc atcataaggt 1980
 ggcagtgtaa ccaacctctt atatcaccta catagacagc tgatagaccg gc 2032

<210> 18
 <211> 586
 <212> PRT
 <213> *Aspergillus nidulans*

<400> 18

Met Pro Arg Arg Trp Ser Ser Leu Ile Ser Ile Thr Ala Ile Phe Leu
 1 5 10 15
 Val Leu Phe Phe Leu Leu His Arg Asn Thr Asp Thr Pro Arg Ala Ala
 20 25 30
 Asn Arg Ala Thr Asn Gly Pro Ala Asn Gly Phe Ala Arg Gln Gln Ser
 35 40 45
 Ile Cys Pro Ser Thr Pro Pro Gln Pro Pro Tyr Asn Arg Thr Ser Thr
 50 55 60
 Gly Gly Phe Asn Trp Gly Glu Ile Pro Val Arg Tyr Pro Val Ser Asp
 65 70 75 80
 Phe Ile Pro Leu Ser Thr Asn Ser Pro Ala Thr Leu Pro Arg Ile Gln
 85 90 95
 Arg Ser Ser Phe Pro Leu Gln Ser Ser Ile Thr Lys Ser Arg Gln Ala
 100 105 110
 Ala Val Lys Gly Ala Phe Gln Arg Ala Trp Thr Ser Tyr Thr Thr His
 115 120 125
 Ala Trp Lys Ala Asp Glu Val Arg Pro Ile Thr Ala Gly Ser Arg Asn
 130 135 140
 Asn Phe Gly Gly Trp Gly Ala Thr Leu Val Asp Asn Leu Asp Thr Leu
 145 150 155 160
 Leu Ile Met Gly Leu Asp Glu Glu Phe Ala Ala Ala Val Asp Ala Leu
 165 170 175
 Ala Asp Ile Glu Phe Ser Pro His Ser Ser Pro Ser Ser Ser Gln Ser
 180 185 190
 Thr Ile Asn Ile Phe Glu Thr Thr Ile Arg Tyr Leu Gly Gly Leu Leu
 195 200 205
 Ala Ala Tyr Asp Leu Thr Gly Cys Arg Glu Thr Arg Leu Leu Asp Lys
 210 215 220
 Ala Ile Gln Leu Gly Glu Met Ile Tyr Thr Ser Phe Asp Thr Glu Asn
 225 230 235 240
 Arg Met Pro Val Pro Arg Trp Asn Leu His Lys Ala Gly Asn Gly Glu
 245 250 255
 Pro Gln Arg Ala Ala Val Gln Gly Val Leu Ala Glu Leu Ala Ser Ser
 260 265 270
 Ser Leu Glu Phe Thr Arg Leu Ser Gln Leu Thr Gly Asp Met Arg Tyr
 275 280 285
 Phe Asp Ala Ala Ser Arg Ile Thr Asp Leu Leu Asp Ser Gln Ala Gly
 290 295 300
 His Thr Arg Ile Pro Gly Leu Trp Pro Val Ser Val Asn Leu Gln Lys
 305 310 315 320
 Gly Asp Leu Thr Arg Gly Ser Thr Phe Ser Phe Gly Gly Met Ala Asp

			325					330					335		
Ser	Ala	Tyr	Glu 340	Tyr	Leu	Gly	Lys	Thr 345	Tyr	Arg	Leu	Leu	Gly 350	Gly	Val
Gly	Lys	Gly 355	Pro	Gln	Tyr	Glu	Arg 360	Leu	Ala	Arg	Asn	Ala 365	Leu	Asp	Ala
Gly	Ile 370	Arg	His	Leu	Leu	Phe 375	Arg	Pro	Met	Thr	Pro 380	Asp	His	Ala	Asp
Ile 385	Leu	Leu	Pro	Gly	Val 390	Ala	His	Ala	Thr	Ser 395	Ser	Ser	Val	Gly	Leu 400
Glu	Pro	Arg	Thr 405	Glu	His	Leu	Ala	Cys	Phe 410	Val	Gly	Gly	Met	Tyr 415	Ala
Leu	Ala	Gly 420	Lys	Leu	Phe	Ser	Asn 425	Gln	Thr	Tyr	Leu	Asp	Thr 430	Gly	Arg
Lys	Leu	Thr 435	Asp	Gly	Cys	Ile	Trp 440	Tyr	Tyr	Asp	Asn 445	Ser	Pro	Leu	Gly
Ile 450	Met	Pro	Glu	Met	Phe 455	Thr	Val	Pro	Ala	Cys 460	Pro	Ser	Val	Ala	Glu
Cys 465	Pro	Trp	Asp	Glu	Thr 470	Arg	Gly	Gly	Ile	Tyr 475	Thr	Tyr	Val	Arg	Asp 480
Gly	His	Tyr	Phe 485	Leu	Arg	Pro	Glu	Ala 490	Met	Glu	Ser	Ile	Phe 495	Tyr	Met
Trp	Arg	Ile 500	Thr	Gly	Asp	Glu	Lys	Tyr 505	Arg	Glu	Ala	Ala	Trp 510	Arg	Met
Phe	Thr 515	Ala	Ile	Glu	Ala	Val	Thr 520	Lys	Thr	Glu	Phe 525	Gly	Asn	Ala	Ala
Val 530	Arg	Asp	Val	Met	Val	Glu 535	Glu	Gly	Asn	Val	Lys 540	Arg	Glu	Asp	Ser
Met 545	Glu	Ser	Phe	Trp	Met 550	Ala	Glu	Thr	Leu	Lys 555	Tyr	Leu	Tyr	Leu	Ile 560
Phe	Gly	Glu	Thr 565	Asp	Leu	Val	Ser	Leu	Asp 570	Asp	Trp	Val	Phe 575	Asn	Thr
Glu	Ala	His 580	Pro	Leu	Arg	Gly	Ala 585	Gly	Ser						

```
<210> 19
<211> 6
<212> DNA
<213> Artificial Sequence
```

```
<220>
<221> variation
<222> (1)
<223> N = G OR A
```


<220>

<221> variation

<222> (4)

<223> N = G OR A

<220>

<223> Description of Artificial Sequence: CONSENSUS
SPLICE SITE

<400> 19

nctnac

6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/27210

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 9/00, 9/24, 15/09, 1/20; C07K 16/00
US CL : 435/69.2, 183, 200; 530/389.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.2, 183, 200; 530/389.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, CAPLUS, EMBASE, MEDLINE, SCISEARCH, USPTO WEST.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	HERSCOVIC ET AL. Isolation of a mouse golgi mannosidase cDNA, a member of a gene family conserved from yeasts to mammals. J. Biol. Chem. 01 April 1994, Vol. 269, No. 13, pages 9864-9871, see especially pages 9870-9871.	1, 3-14 ----- 1, 3-14
X --- Y	LAL ET AL. Isolation and expression of murine and rabbit cDNAs encoding an alpha-mannosidase involved in the processing of asparagine-linked oligosaccharides. J. Biol. Chem. 01 April 1994, Vol. 269, No. 13, pages 9872-9881, see entire article.	1, 3-14 ----- 1, 3-14
Y	TURCO ET AL. Altered G-protein glycosylation in vesicular stomatitis virus-infected glucose-deprived baby hamster kidney cells. J. Biol. Chem. 10 August 1982, Vol. 257, No. 15, pages 8674-8679, see entire article.	1, 3-14



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 JANUARY 2001

Date of mailing of the international search report

28 FEB 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MANJUNATH RAO

Telephone No. (703) 308-0198

TERRY J. DEY
PARALEGAL SPECIALIST
TECHNOLOGY CENTER 1600

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/27210

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 5,837,836 A (FRIDERICI ET AL.) 17 November 1998 (17/11/98) see entire document.	2 --- 2
X --- Y	US 5,578,484 A (HOROSZEWICZ) 26 November 1996 (26/11/96) see entire document.	2 --- 2
X --- Y	EADES ET AL. Identification and analysis of a class 2 alpha-mannosidase from <i>Aspergillus nidulans</i> . <i>Glycobiology</i> . 1998, Vol. 8, pages 17-33, see entire document.	1-14 --- 1-14
X --- Y	INOUE ET AL. Molecular cloning and nucleotide sequence of the 1,2-alpha-D-mannosidase gene, msds, from <i>Aspergillus saitoi</i> and expression of the gene in yeast cells. <i>Biochimica et Biophysica Acta</i> . 1995, Vol. 1253, pages 141-145, see entire document.	1-14 --- 1-14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/27210

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/27210

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1, 3-7, 11, 13-14, drawn to a purified mannosidase, polynucleotides and method of making.

Group II, claim 2, drawn to a binding agent that binds the purified protein.

Group III, claims 8-10 and 12, drawn to a method of altering glycosylation pattern of a macromolecule.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Mannosidases, their polynucleotides, binding agents and method of altering the glycosylation pattern of macromolecules are well known in the prior art. Thus, the above invention, when considered as a whole does not contribute over the prior art (see Turco et al. J. Biol. Chem., 1982, Vol. 257(15):8674-8679).